Pete Coffey
Overview
Explore the profile of Pete Coffey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
279
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vitillo L, Anjum F, Hewitt Z, Stavish D, Laing O, Baker D, et al.
Stem Cell Reports
. 2023 Feb;
18(3):782-797.
PMID: 36801002
Chromosome 20 abnormalities are some of the most frequent genomic changes acquired by human pluripotent stem cell (hPSC) cultures worldwide. Yet their effects on differentiation remain largely unexplored. We investigated...
2.
Chorlton J, Hollowood Z, Dyer C, Lockhart D, Boekman P, McCafferty K, et al.
EClinicalMedicine
. 2022 Aug;
51:101604.
PMID: 35996565
Background: A potential immunotherapeutic role for AZD1656 (a glucokinase activator) in the treatment of COVID-19 was hypothesized. The ARCADIA trial investigated the safety and efficacy of AZD1656 in diabetic patients...
3.
Vitillo L, Tovell V, Coffey P
Curr Eye Res
. 2019 Nov;
45(3):361-371.
PMID: 31777296
Retinal pigment epithelium (RPE) degradation is central to the onset and progression of age-related macular degeneration (AMD), a growing and currently incurable form of blindness.Due to its key role in...
4.
Eastlake K, Wang W, Jayaram H, Murray-Dunning C, Carr A, Ramsden C, et al.
Stem Cells Transl Med
. 2019 May;
8(8):775-784.
PMID: 31037833
Glaucoma is one of the leading causes of blindness, and there is an ongoing need for new therapies. Recent studies indicate that cell transplantation using Müller glia may be beneficial,...
5.
Lane A, Philip L, Ruban L, Fynes K, Smart M, Carr A, et al.
Stem Cells Transl Med
. 2014 Oct;
3(11):1295-304.
PMID: 25273541
Human embryonic stem cells (hESCs) are a promising source of retinal pigment epithelium (RPE) cells: cells that can be used for the treatment of common and incurable forms of blindness,...
6.
Lidster K, Jackson S, Ahmed Z, Munro P, Coffey P, Giovannoni G, et al.
PLoS One
. 2013 Nov;
8(11):e79188.
PMID: 24223903
Multiple sclerosis is an immune-mediated, demyelinating and neurodegenerative disease that currently lacks any neuroprotective treatments. Innovative neuroprotective trial designs are required to hasten the translational process of drug development. An...
7.
Catchpole I, Germaschewski V, Hoh Kam J, Lundh von Leithner P, Ford S, Gough G, et al.
PLoS One
. 2013 Jun;
8(6):e65518.
PMID: 23799019
Age-related macular degeneration (AMD) is a leading cause of legal blindness in the Western world. There are effective treatments for the vascular complications of neo-vascular AMD, but no effective therapies...
8.
Robbie S, Lundh von Leithner P, Ju M, Lange C, King A, Adamson P, et al.
Invest Ophthalmol Vis Sci
. 2013 Feb;
54(2):1490-500.
PMID: 23385800
Purpose: Two noninvasive delivery strategies for VEGF/PDGF receptor tyrosine kinase inhibitors (RTKI) were explored that exploited uveal retention as a means for establishing an ocular drug depot: a single oral...
9.
Roberts I, Baila S, Rice R, Janssens M, Nguyen K, Moens N, et al.
Biotechnol Lett
. 2012 Sep;
34(12):2307-15.
PMID: 22983716
The commercialisation of human embryonic stem cell derived cell therapies for large patient populations is reliant on both minimising expensive and variable manual-handling methods whilst realising economies of scale. The...
10.
Coffey P
Cell Stem Cell
. 2012 Jan;
10(1):1-2.
PMID: 22226345
The innate capacity of adult somatic cells has many potential applications in regenerative medicine. In this issue of Cell Stem Cell, Salero et al. (2012) describe an adult retinal stem...